Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857506 · ClinicalTrials.gov registry record · Phase 2
Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)
A Phase 2 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT00857506 is a Phase 2 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 152 participants.
The verdict
NCT00857506, a Phase 2 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
The primary objective of this protocol is to determine if brain amyloid imaged with florbetapir F 18 (18F-AV-45) PET scans is predictive of progressive cognitive impairment during the subsequent 36 months for groups of: normal controls, mild cognitive impairment and Alzheimer's disease. Hypothesis 1: The probability a subject will experience progressive cognitive impairment within 36 months of imaging will be greater in subjects whose 18F-AV-45 PET scan was rated amyloid positive compared to subjects whose PET scan was rated amyloid negative. The secondary objective is to determine the stability, over 36 months of a clinical diagnosis, of AD in patients with an amyloid positive 18F-AV-45 PET. Hypothesis 2: The diagnosis of AD will remain unchanged in patients whose PET scan were rated as amyloid positive.
Interventions
- DRUG florbetapir F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00857506
The ClinicalTrials.gov registry entry for NCT00857506 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which florbetapir F 18 is the first listed.
NCT00857506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00857506 about?
NCT00857506 is a clinical study titled "Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)". The primary objective of this protocol is to determine if brain amyloid imaged with florbetapir F 18 (18F-AV-45) PET scans is predictive of progressive cognitive impairment during the subsequent 36 months for groups of: normal controls, mild cognitive impairment and Alzheimer's disease. Hypothesis ...
What is the current status of trial NCT00857506?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2009-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00857506?
The interventions under investigation include: florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT00857506?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.